Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas

Matthias Holdhoff, Xiaobu Ye, Jaishri O. Blakeley, Lindsay Blair, Peter C. Burger, Stuart A. Grossman, Luis A. Diaz

Research output: Contribution to journalArticlepeer-review

Abstract

This study was conducted to assess the current pattern of use and the impact of available molecular predictive and prognostic biomarkers on clinical care in patients with glioblastoma (GBM). An online questionnaire consisting of 15 questions about the frequency of use and clinical utility of tissue-based molecular tests was distributed to 1,053 members of the Neuro-Oncology Community in the United States. A total of 320 responses (30.4 %) were collected. 73 respondents who did not see GBM patients were excluded from analysis. MGMT promoter methylation testing (MGMT-meth) was the most commonly requested (37.2; 95 % CI, 31-44), followed by EGFR amplification (22.7; 95 % CI, 18-28), co-deletion of 1p/19q (22.3 %), EGFR expression (21.5 %), P53 mutation (19.8 %), PTEN mutation or deletion (17.4 %), EGFRvIII mutation (12.1 %), IDH1/2 mutation (12.1 %), PDGFR (4.5 %), and PIK3CA (0.8 %). The perceived utility of these studies was variable between participants. A small percentage of respondents felt that any of the studies were always or almost always helpful in clinical decision making (MGMT-meth 10.9 %; range, 0-13.8 %), but more frequently never or almost never helpful (MGMT-meth 25.9 %; range, 25-54.7 %). 26.7 % reported not to routinely order any of these studies. Although molecular markers are frequently ordered for patients with GBM, only a minority of clinicians ordering these tests report that the results influence clinical decision-making. Molecular markers that are likely to affect patient care should be ordered with the goal to maximize benefit for patients and to avoid non-actionable results and additional costs.

Original languageEnglish (US)
Pages (from-to)279-285
Number of pages7
JournalJournal of neuro-oncology
Volume110
Issue number2
DOIs
StatePublished - Nov 1 2012

Keywords

  • Glioblastoma
  • MGMT promoter methylation
  • Molecular biomarker
  • Personalized medicine
  • Prognostic biomarker

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas'. Together they form a unique fingerprint.

Cite this